B and T Lymphocyte Attenuator Down-regulation by HIV-1 Depends on Type I Interferon and Contributes to T-Cell Hyperactivation by Zhang, Zheng et al.
M A J O R A R T I C L E
B and T Lymphocyte Attenuator Down-regulation
by HIV-1 Depends on Type I Interferon and
Contributes to T-Cell Hyperactivation
Zheng Zhang,1,a Xiangsheng Xu,1,a Jiyun Lv,1 Shuye Zhang,1 Lanlan Gu,1 Junliang Fu,1 Lei Jin,1 Haiying Li,3 Min Zhao,3
Jiyuan Zhang,1 Hao Wu,2 Lishan Su,4,5 Yang-Xin Fu,4,6 and Fu-Sheng Wang1,4
1Research Center for Biological Therapy and 2Department of Infectious Diseases, Beijing 302 Hospital; 3Department of Infectious Diseases, Beijing You-
An Hospital Affiliated with Capital University of Medical Science; 4Center for Infection and Immunity, Institute of Biophysics, Chinese Academy of
Science, Beijing, China; 5The Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, School of Medicine, The
University of North Carolina, Chapel Hill; and 6Department of Pathology, University of Chicago, Illinois
Background. Nonspecific T-cell hyperactivation is the main driving force for human immunodeficiency virus
(HIV)–1 disease progression, but the reasons why the excess immune response is not properly shut off are poorly
defined.
Methods. Eighty-five HIV-1–infected individuals were enrolled to characterize B and T lymphocyte attenuator
(BTLA) expression and function. Infection and blockade assays were used to dissect the factors that influenced
BTLA signaling in vitro.
Results. BTLA expression on overall CD41 and CD81 T cells was progressively decreased in HIV-1
infection, which was directly correlated with disease progression and CD41 T-cell differentiation and activation.
BTLA1CD41 T cells from HIV-1–infected patients also displayed an altered immune status, which was indicated
by reduced expression of naive markers but increased activation and exhaustion markers. Cross-linking of BTLA
can substantially decrease CD41 T-cell activation in vitro. This responsiveness of CD41 T cells to BTLA-
mediated inhibitory signaling was further found to be impaired in HIV-1–infected patients. Furthermore, HIV-1
NL4-3 down-regulated BTLA expression on CD41 T cells dependent on plasmacytoid dendritic cell (pDC)-
derived interferon (IFN)-a. Blockade of IFN-a or depletion of pDCs prevents HIV-1-induced BTLA down-
regulation.
Conclusions. HIV-1 infection potentially impairs BTLA-mediated signaling dependent on pDC-derived IFN-a,
which may contribute to broad T-cell hyperactivation induced by chronic HIV-1 infection.
A chronic generalized immune activation is now
increasingly being recognized to be the main driving
force for T-cell depletion, loss of antiviral immunity,
and disease progression during chronic human
immunodeficiency virus (HIV)-1–infection [1, 2].
Clinical evidence has indicated that T-cell activation
levels are predictive of an adverse prognosis for the
HIV-1–infected patients [3, 4]. Additional evidence
for this pathogenesis is the lack of disease progression
in simian immunodeficiency virus (SIV)-infected
monkeys that quickly down-regulate the initial in-
flammatory response upon SIV infection [5]. Addi-
tional studies indicated that the immune activation is
driven directly by T cells that, in a cognate fashion,
recognize HIV-1 proteins [6], by activation of plas-
macytoid dendritic cells (pDCs) through Toll-like
receptors (TLRs) [7] and by bacterial products
translocated from gut to blood [8]. Thus, excess
immune activation has been regarded as deleterious to
the host; the interventions to temper immune hyper-
activation, therefore, may prevent disease progression
to AIDS. However, it is still unknown why this excess
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immune activation cannot be limited or properly shut off
during HIV-1 infection.
Recently, some cell-surface costimulatory molecules have
been demonstrated to have a substantial impact on the T-cell
activation [9]. These cosignaling pathways play overlapping
and distinct regulatory roles for each lymphocyte subset
during their various stages of immune response, such that
immune responses occur in the correct intensity and manner
[9]. In particular, some immune-inhibitory molecules, such
as PD-1 [10–13], CTLA-4 [14], and Tim-3 [15], have been
implicated mediators of T-cell exhaustion during chronic
HIV-1 infection. Other studies have further shown that ex-
hausted T cells in fact express many coinhibitory molecules
[16], and these coinhibitory receptors regulate T-cell re-
sponses through multiple, complex patterns [17]. Although
these pioneering studies clearly indicate that coinhibitory
signaling mediates T-cell exhaustion and partially leads to
HIV-1 persistence, it is necessary to define whether these
inhibitory pathways experience functional deficits that may
be responsible for the immune hyperactivation in chronic
HIV-1 infection.
B and T lymphocyte attenuator (BTLA, CD272), the most
recently recognized member of the CD28 family, is primarily
expressed by the majority of lymphocytes [18]. Interaction
with its ligand, herpes virus entry mediator (HVEM) induces
tyrosine phosphorylation of immunoreceptor tyrosine-based
inhibition motifs [19] and attenuates T-cell activation [20].
In vitro, BTLA ligation can send a constitutive ‘‘off’’ signal to
T cells and maintain T-cell tolerance [21–23]. BTLA-de-
ficient mice generally develop exacerbated disease, suggest-
ing that BTLA predominantly regulates immune responses
negatively [24, 25]. In human diseases, BTLA was found to
be persistently expressed by melanoma tumor antigen-spe-
cific CD8 T cells, thus inhibiting their anti-tumor function
[26]. These studies have defined the inhibitory roles of BTLA
in regulating immune responses; however, little is known
regarding the functional role of BTLA in chronic HIV-1
infection.
Our previously preliminary data indicated that BTLA was
down-regulated and associated with the decrease in CD41 T-
cell counts and the increase of plasma HIV-1 loads [27]. The
present study greatly extends our previous data and further
confirms that BTLA expression on T cells is progressively
down-regulated during chronic HIV-1 infection. The BTLA
down-regulation was dependent on pDC-derived interferon
(IFN)-a induced by HIV-1 isolates in vitro and that it im-
paired BTLA-mediated inhibitory signaling on CD41 T-cell
activation, thus contributing to broad T-cell activation in
chronic HIV-1 infection. Enhancing BTLA function may
therefore present an alternative therapeutic strategy for
overcoming aggressive immune activation in chronic HIV-1
infection.
SUBJECTS, MATERIALS, AND METHODS
Subjects
Eighty-five HIV-1–infected individuals were enrolled in our
study. They were divided into 3 groups according to their in-
fection status (Table 1.) [12, 28]. Twenty-six HIV-1–uninfected
subjects were used as healthy control subjects. All HIV-
1–infected subjects were divided into 3 groups, including a
cohort of 14 long-term nonprogressors (LTNPs; defined as
those who had a persistent peripheral CD41 T-cell count
. 500 cells/lL and plasma HIV-1 RNA level , 500 copies/mL,
who had received no antiretroviral therapy, and who had
experienced no clinical signs of disease forR10 years), 44 typical
progressors (defined as those who exhibited a typical progressive
disease with peripheral CD41 T-cell counts .200 cells/lL
and plasma HIV-1 RNA level .1000 copies/mL, without
receiving antiviral treatment, and no AIDS-defining condition),
and 27 patients with AIDS (defined as those who had an AIDS-
defining condition, according to theWorld Health Organization
classification, including a progressive decrease in peripheral
CD41 T-cell counts to , 200 cells/lL and a plasma viral RNA
level . 1000 copies/mL, without receipt of antiviral treatment,
and present or previous opportunistic infections). The majority
of these individuals (89.4%) were paid blood donors who had
become infected through illegal blood collection during the
period 1994–1995, whereas other patients had been infected
with HIV-1 via sexual transmission. The study protocol was
approved by the ethics committee of our unit, and written
informed consent was obtained from each subject.
Antibodies and Reagents
All antibodies were purchased from BD Biosciences, except
for biotinylated anti-BTLA (clone MIH26); its isotype control
antibody IgG2a-Biotin, allophycocyanin (APC)-, and phy-
coerythrin (PE)-conjugated streptavidin (eBioscience); and
APC-conjugated major histocompatibility complex class I
pentamers (ProImmune), which are reported to be frequently
targeted by HIV-1–specific T cells (p17 gag; SLYNTVATL,
SL9) [29], cytomegalovirus (CMV; pp65 495–503;
NLVPMVATV, NV9), or influenza virus epitopes (matrix 58-
66; GILGFVFTL, GL9) [30]. Anti-HLA-A2 Ab (Catalog
Number: 551285, clone BB7.2; BD Pharmingen) was used to
determine genotypes of the enrolled subjects. The pentamer
analysis was limited to 36 of HLA-A2–positive subjects, in-
cluding 12 healthy subjects, 7 LTNPs, and 17 typical pro-
gressors/patients with AIDS. All HIV-1 isolates were prepared
according to previous described protocols [31]. Anti-HIV
drug nevirapine, HIV-1 gp120 monoclonal antibody (IgG1
B12), and monoclonal antibodies against human IFN-a and
IFN-b were obtained through the National Institutes of
Health AIDS Research and Reference Reagent Program.
Chloroquine was obtained commercially (Sigma-Aldrich).
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Cytokines IFN-a, interleukin (IL)–1b, IL-6, IL-17, IL-7, and
IL-15 were purchased from Peprotec, and anti-IFN-a/b
receptor chain 2 Ab (anti-IFN-aR) was purchased from R&D
Systems.
Cell Isolation and Phenotypic Analysis
Peripheral blood mononuclear cells (PBMCs) were isolated
from freshly heparinized blood, and CD41 T cells were purified
by positive selection using the MiniMACS system (Miltenyi
Biotech). In pDC depletion experiments, PBMCs were labeled
with fluorescein isothiocyanate (FITC)-conjugated anti-BDCA-2
and APC-conjugated anti-CD123 (Miltenyi Biotech) and were
then sorted using a FACSAria cell sorter (Becton Dickinson).
Isolated memory CD41 T cell and pDC populations were
.95% in purity, whereas pDC-depleted PBMCs just contained
few pDCs (,0.001% BDCA-21CD1231 pDCs).
PBMCs were labeled with anti-CD3-peridin chlorophyll
protein (PerCP), anti-CD4 or anti-CD8-FITC, anti-CD8 or
pentamer-APC, and anti-BTLA-PE for measuring BTLA ex-
pression on total T-cells subsets or on virus-specific CD81
T cells. For CD41 T subset staining, PBMCs or purified CD41
T cells were incubated with a cocktail of antibodies: CD4-PerCP,
BTLA-PE, CD45RO-APC, and CD27-FITC. To characterize
the phenotypes of BTLA1 and BTLA–CD41 T cells, PBMCs
were stained with anti-CD3-FITC, anti-CD4-PerCP, anti-BTLA-
APC, and PE-conjugated anti-CD127, anti-CD38, anti-PD-1,
anti-CD95, anti-ki67, and corresponding isotype antibodies.
The cells were then washed, fixed, and analyzed using a FACS-
Calibur flow cytometer (Becton Dickinson) and FlowJo software
(TreeStar).
CD41 T-Cell Activation and Functional Analysis
Freshly isolated PBMCs were stimulated with anti-CD3/CD28
antibodies (each 1 lg/mL) in medium, plus either plate-coated
anti-BTLA (10 lg/mL; clone MIH26, eBioscience, San Diego,
CA) or isotype antibodies for 24 hours. The cells were then
collected, and CD69, CD38 and CD25 expressions were analyzed
by FACS. PBMCs were also stimulated with anti-CD3/CD28
antibodies (each 1 lg/mL) or PMA/ionomycin (50 ng/mL and
1 lg/mL, respectively), plus either plate-coated anti-BTLA
(10 lg/mL) or isotype antibodies for 6 h. GolgiStop (BD
PharMingen) was added into cells after 2 h of stimulation.
The cells were then labeled with surface antibodies and in-
tracellular anti-IFN-c-FITC and anti-IL-2-APC, as previously
described [12, 30].
Cytokine Stimulation and HIV-1 Infection Assay
PBMCs from healthy subjects were stimulated with IFN-a
(1000 IU/mL), with or without anti-IFN-a/b receptor chain 2
(10 lg/mL), IL-7, IL-15, IL-1b, IL-6, and IL-17 for 5 days. The
cells were then washed and were detected BTLA expression was
detected on T cells. For the HIV-1 infection assay, fresh PBMCs
(13 106 cells/mL) were incubated in 96-well plates with 100 lL
mock or diluted HIV-1 R3A, R3B, and NL4-3 (50 ng/mL p24
antigen) virus supernatants, along with the anti-HIV-1 reagents
anti-IFN-a/b (5 ng/mL), B12 IgG (10 lg/mL), nevirapine
(5 lmol/L), and chloroquine (50 lmol/L) in the presence of
IL-2 (20 U/mL) for 3 days. Alternatively, PBMCs, PBMCs-
pDCs, CD41 T cells, and CD41 T cells plus pDCs (10:1) were
incubated with NL4-3 isolates for 5 days. The cells were then
collected for evaluation of BTLA expression on CD4 T cells
with use of FACS-Calibur. 7-AAD was used to exclude dead
cells. At least 10,000 live cells were acquired per run.
Semi-quantitative Real-time Polymerase Chain Reaction
Total RNA was extracted from the isolated total or CD41 T-cell
subsets using an RNAeasy Mini Kit (Qiagen). Total RNA was
extracted and then reversed-transcribed to cDNA using oligo (dT)
with avian myeloblastosis virus reverse transcriptase (Invitrogen)
at 42C for 30 min and 95C for 5 min. The quantitative
expressions of BTLA transcripts were subsequently determined
using fluorogenic dye SYBR Green and primers. Glyceraldehyde





nonprogressors Typical progressors Patients with AIDS
No. of subjects 26 14 44 27
Age, median years (range) 32 (19–31) 36 (26–43) 45 (32–56) 49 (25–61)
Sex, no. of men/no. of women 17/9 8/6 34/10 17/10
CD41 T-cell count, median cells/lL
(range)
NA 569 (507–1020)a 339 (203–482)a 112 (55–189)





Blood transfusion NA 14 40 23
Sex NA 1 4 4
NOTE. NA, not applicable
a P , .05, compared with patients with AIDS.
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3-phosphate dehydrogenase was used to normalize the samples in
each PCR reaction. Bothmelting-curve and gel-migration analyses
were used to ensure the absence of nonspecific and primer-dimer
products. The results are expressed as relative mRNA quantifica-
tion calculated using the 22DCt method.
Statistical Analysis
All data were analyzed using SPSS software (SPSS Inc). The
Kruskal–Wallis H nonparametric test was performed for mul-
tiple comparisons among R3 groups. Statistical differences
between 2 groups were determined by the Mann–Whitney
nonparametric U test. Data from the same individuals were
compared by the Wilcoxon matched-pairs t test. Correlations
between variables were evaluated using the Spearman rank
correlation test. For all tests, a P value of ,.05 was considered
statistically significant.
RESULTS
BTLA Expression Is Progressively Down-regulated by All
T Cells in Patients With Chronic HIV-1 Infection
We first determined BTLA expression profiles at cellular levels in
healthy donors, and we found that BTLA was mainly expressed by
B cells, CD41 T cells and CD81 T cells, NKT cells, and monocytes
rather than on NK cells (data not shown). We further monitored
BTLA expression on both CD41 and CD81 T cells in 85 HIV-
1–infected individuals and 27 healthy subjects (Figure 1A). We
found that BTLA expression on T cells was significantly down-
regulated in HIV-1–infected subjects, compared with healthy
subjects. Importantly, LTNPs exhibited higher levels of BTLA
expression on CD41 and CD81 T cells than did typical
progressors and patients with AIDS, while the lowest levels of
BTLA expression on T cells were observed in patients with AIDS
Figure 1. B and T lymphocyte attenuator (BTLA) expression on human T cells during chronic human immunodeficiency virus (HIV)-1–infection. A,
Representative dot plots of BTLA staining in T cells isolated from healthy subjects and HIV-1–infected individuals. Values in the upper-left and upper-right
quadrants represent the percentages of CD41 T cells and CD81 T cells that express BTLA, respectively. B and C, Statistical analysis of BTLA percentage
and mean fluorescence intensity in CD41 T cells (B) and CD81 T cells (C) in healthy control subjects (HC; n5 26), long-term nonprogressors (LTNP; n5
14), typical progressors (TP; n 5 44), and patients with AIDS (n 5 27). D, Representative gel analysis of semi-quantitative real-time polymerase chain
reaction products of BTLA mRNA transcripts extracted from purified CD41 T cells from 2 HIV-1 infected TPs and 2 HCs. P, patient; H, healthy subject. E,
Statistical analysis of BTLA mRNA expression in CD41 T cells from HIV-1-infected TPs/patients with AIDS (n5 11) and HCs (n5 5). F, Representative dot
plots of BTLA-expressing HIV-, cytomegalovirus (CMV)-, or influenza virus–specific CD81 T cells from HIV-1-infected patients and HCs. Values in the
upper-right quadrant represent the percentage of pentamer-positive CD81 T cells that express BTLA. G, The frequency and mean fluorescence of BTLA
expressed on HIV-, CMV-, or influenza virus–specific CD81 T cells in the different study groups. In panels B, C, E, and G, each dot represents 1 individual,
and horizontal bars represent the median values. Multiple comparisons were made using the Kruskal-Wallis H nonparametric test among the different
groups. The Mann-Whitney U test was used to compare data from 2 different groups. The significant P values are shown.
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(Figure 1B and 1C). We also found that BTLA mRNA expression
in purified CD41 T cells was also significantly lower in HIV-
1–infected patients than in healthy subjects (Figure 1D and 1E).
The data clearly indicate that BTLA expression on T-cell subsets is
progressively down-regulated during chronic HIV-1 infection.
Next, we found that BTLA expression was similar in HIV-
1–specific versus CMV-specific and influenza-specific pentam-
er-positive CD81 T cells in typical progressors/patients with
AIDS (Figure 1F). As compared with healthy subjects, BTLA
expression on both CMV-specific and influenza virus-specific
pentamer-positive cells was significantly reduced in typical pro-
gressors/patients with AIDS (Figure 1F and 1G). These data in-
dicate that BTLA expression is also progressively down-regulated
in HIV-specific CD81 T cells during HIV-1 infection.
BTLA Down-regulation on CD4 T Cells Is Associated With
Disease Progression and Immune Activation in Chronic HIV-1
Infection
We further examined the relationships between BTLA expression
on T cells and plasma viral load, peripheral CD41 T-cell counts
and CD38 expression on CD8 T cells, which has been widely used
as an activation marker predicting disease progression in HIV-1
infection [1, 3]. We found that the BTLA1 cell percentage in
total CD41 T cells was positively correlated with peripheral CD41
T cell count but inversely correlated with plasma viral load and
CD38 expression on CD81 T cells (Figure 2A). Simultaneously,
we also found that BTLA expression on total CD41 T cells was
negatively correlated with PD-1 [10, 12] and Ki67 [32] expression
levels, but it was positively correlated with CD127 [33] expression
in typical progressors/patients with AIDS (Figure 2B). These
data indicate that BTLA down-regulation in CD41 T cells can
potentially serve as a marker of disease progression and immune
hyperactivation in HIV-1 infection.
BTLA Expression Is Down-regulated in Various Differentiated
CD41 T-Cell Subsets in HIV-1 Infection
We then examined the distribution of BTLA expression in
CD41 naive T cell (Tn), central memory T cell (Tcm), and
effector memory T cell (Tem) subsets on the basis of CD45RO
and CD27 expression [34]. As in our previous report [12],
chronic HIV-1 infection leads to a significant decrease in naive
CD41 T-cell subset levels but a continuous increase in memory
CD41 T-cell subset levels in HIV-1–infected typical progressors/
patients with AIDS (Figure 3A, left). Importantly, we found that
BTLA expression was more predominant in Tn cells in healthy
subjects but gradually decreased in the Tn, Tcm, and Tem
populations in HIV-1–infected individuals, regardless of disease
status (Figure 3A, right). Pooled data further confirmed that
BTLA expression on the 3 subsets was significantly decreased
in HIV-1-infected subjects, compared with healthy subjects
(Figure 3B). These data indicate that persistent HIV-1 infection
leads to a significant loss of BTLA expression on both naive and
memory CD41 T-cell subsets.
Figure 2. B and T lymphocyte attenuator (BTLA) down-regulation and human immunodeficiency virus (HIV)-1 disease progression. The correlation
analysis is between BTLA expression on CD41 T cells with CD41 T-cell numbers (n5 71), HIV load (n5 71), and CD38 expression on CD8 T cells (n5 30;
A) as well as the expression of Ki67 (n 5 18), PD-1 expression (n 5 30), and CD127 (n 5 21; B) on CD4 T cells in HIV-1–infected patients. P values are
shown. The Spearman rank correlation test was used to evaluate the correlations between variables.
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BTLA1CD41 T Cells Display an Altered Immune Status in HIV-1
Infection
We next determined whether HIV-1 infection influences
BTLA1CD41 T-cell status. In healthy subjects, BTLA1CD41
T cells often displayed an immature profile, with 65% Tn, 30%
Tcm, and 5% Tem subsets, whereas BTLA– CD41 T cells
displayed a relatively mature profile, with 25% Tn, 45% Tcm,
and 30% Tem subsets (Figure 4A). This distribution was sig-
nificantly altered in BTLA1 but not in BTLA– CD41 T cells in
HIV-1–infected subjects. Similar alterations were also occurred
in CD38 (activation), CD95 (preapoptosis), PD-1 (exhaustion),
Ki67 (proliferation), and perforin (cytolytic function) (Figure
4B). Compared with healthy subjects, patients with chronic
HIV-1 infection had markedly increased CD38, CD95, PD-1,
Ki67, and perforin expression and decreased CD127 expression
in BTLA1 CD41 T-cell subsets, but HIV-1 infection seldom
influenced the expression of these markers in the BTLA– CD41
T-cell population, except for CD38, which was also elevated in
HIV-1–infected subjects. This comprehensive analysis suggests
that HIV-1 infection significantly skews BTLA1 rather than
BTLA– CD41 T cells toward differentiation and maturation.
HIV-1 Induces BTLA Down-regulation on CD41 T Cells
Dependent on pDC-Derived IFN-a In Vitro
We investigated the impacts of IFN-a; inflammatory cytokines
IL-1b, IL-6, and IL-17; and c-chain cytokines IL-7 and IL-15 on
Figure 3. B and T lymphocyte attenuator (BTLA) down-regulation in CD41 T-cell subsets in human immunodeficiency virus (HIV)-1–infected individuals.
A, Representative BTLA expressions on CD41 T-cell subsets from a healthy subject and an HIV-1-infected individual. The percentages of each CD41 T-cell
population are shown in each quadrant (left panel). The BTLA percentages in each CD41 T-cell population are shown as histograms (right panel). B,
Statistical analysis of the BTLA expression levels in CD41 T-cell subsets in the different study groups. *P, .05. Multiple comparisons were made using
the Kruskal-Wallis H nonparametric test among the different groups. The Mann-Whitney U test was used to compare data from 2 different groups. Tn,
naive T cells; Tcm, central memory T cells; Tem, effector memory T cells.
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BTLA expression in vitro. We found that IFN-a can signifi-
cantly reduce BTLA expression on CD41 T cells. Blockade of
IFN-a pathway using anti-IFN-a receptor reversed the BTLA
down-regulation. In contrast, IL-1b, IL-6, IL-17, IL-7, and IL-15
failed to decrease BTLA expression in vitro (Figure 5A). In
addition, we found that various HIV-1 isolates can also directly
down-regulate BTLA expression on CD41 T cells in vitro,
particularly NL4-3 isolate induced the most significant BTLA
down-regulation compared with R3A and R3B (Figure 5B).
More importantly, we found that anti-IFNa/b, B12 (the an-
tagonist of viral gp120 binding to CD41 T cells), and chloro-
quine (endocytosis inhibitor) but not nevirapine (which blocks
viral replication) can efficiently prevent NL4-3-induced BTLA
down-regulation (Figure 5C). Pooled data further confirmed
these observations (Figure 5D). Interestingly, the depletion of
pDCs from PBMCs partially blocked NL4-3-induced BTLA
down-regulation on CD41 T cells (Figure 5E, left). Notably,
NL4-3 infection of purified CD4 T cells substantially reduces
BTLA expression, whereas addition of the pDCs in vitro further
decreased BTLA expression on CD41 T cells. Blockade of the
IFN-a-mediated pathway using both anti-IFN-a/b antibodies
and anti-IFN-a receptor antibodies reversed the BTLA down-
regulation on CD41 T cells (Figure 5E, right). These lines of
evidence indicate that HIV-1 can down-regulate BTLA expres-
sion on CD41 T cells via induction of pDC-derived IFN-a,
although some other alternative molecular pathways may be
responsible for BTLA down-regulation in HIV-1 infection.
BTLA-Mediated Inhibition on CD41 T-Cell Activation and
Function Is Impaired in HIV-1 Infection
We further investigated the functional relevance of
diminished BTLA expression on CD41 T cells in HIV-1–
infected subjects. Cross-linking of BTLA using an agonistic
anti-BTLA monoclonal Ab (MIH26) substantially decreased
Figure 4. B and T lymphocyte attenuator (BTLA)–positive CD41 T cells and abnormal immune status in human immunodeficiency virus (HIV)–1
infection. A, The analysis of percentages of BTLA1 and BTLA– CD41 T cells in naive T cell (Tn), central memory T cell (Tcm), and effector memory T-cell
(Tem) subsets in healthy subjects and HIV-1–infected individuals. B, The phenotypic profiles of BTLA1 and BTLA– CD41 T cells analyzed for CD38, CD95,
CD127, perforin, PD-1, and Ki67 expression in healthy subjects (n5 16) and HIV-1-infected subjects (8 long-term nonprogressors 10 typical progressors,
and 9 patients with AIDS). *P ,.05, **P ,.01. Multiple comparisons were made using the Kruskal-Wallis H nonparametric test among the different
groups. The Mann-Whitney U test was used to compare data from 2 different groups.
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CD69, CD38, and CD25 expression on CD41 T cells in
healthy subjects (Figure 6A). However, the inhibition of
BTLA cross-linking on CD38, CD25, and CD69 expression
was significantly reduced in typical progressors/patients with
AIDS (Figure 6B). Similar results were also demonstrated
in cytokine production by CD4 T cells. Anti-BTLA cross-
linking significantly inhibits anti-CD3/CD28 and PMA/
ionomycin-induced IL-2 and IFN-c production by CD41 T
cells in healthy subjects (Figure 6C). This BTLA-mediated
suppression of IL-2 and IFN-c production was significantly
reduced in typical progressors/patients with AIDS, com-
pared with healthy subjects (Figure 6D). These data indicate
that BTLA-mediated suppression of CD41 T-cell activation
and function is significantly impaired in chronic HIV-1
infected typical progressors/patients with AIDS.
DISCUSSION
Nonspecific T-cell hyperactivation is associated with HIV-1
disease progression, but its mechanisms are poorly defined.
Here, we present several novel observations that may shed new
light on the mechanism of immune activation in HIV-1 in-
fection: (1) BTLA is progressively down-regulated in HIV-1–
infected patients, and this loss of BTLA expression is associated
with skewed CD4 T-cell activation and differentiation; (2) BTLA
down-regulation is dependent on IFN-a from pDCs, which is
induced by HIV-1 isolates; and (3) BTLA-mediated inhibitory
signaling on T-cell activation and function is severely impaired
in HIV-1–infected patients. These findings have unveiled the
regulatory role of BTLA in HIV-1 infection.
We first observed that BTLA expression was progressively
down-regulated by both CD41 and CD81 T cells in LTNPs,
typical progressors, and patients with AIDS, strongly suggesting
that BTLA expression may potentially serve as a surrogate
marker for HIV-1 immune hyperactivation and disease pro-
gression. We further identified the BTLA expression patterns
differing from the expression of other coinhibitory molecules,
such as PD-1 and CTLA-4, during HIV-1 infection [10–13].
BTLA was highly constitutively expressed by T cells, but it was
down-regulated by HIV-1 infection. By contrast, PD-1 and
CTLA-4 were only slightly expressed by a small fraction of ex-
hausted T cells, and are both up-regulated by HIV-1 infection
Figure 5. B and T lymphocyte attenuator (BTLA) down-regulation on CD41 T cells is dependent on pDC-derived interferon (IFN)-a induced by human
immunodeficiency virus (HIV)–1 exposure. A, Representative histograms indicating the effects of various cytokines on BTLA expression on CD4 T cells
from healthy subjects in vitro. Values represent the BTLA percentages and mean fluorescence intensity (MFI) on CD41 T cells. The data are representative
of 3 independent experiments. B, Representative histograms indicating the effects of various HIV-1 isolates on BTLA expression by CD41 T cells in vitro.
Values represent the BTLA percentages and MFI on CD41 T cells. The data are representative of 4 independent experiments. C, Representative
histograms indicating that the CD4 interaction (B12 antibody), endocytosis (chloroquine), and IFN-a (anti-IFN-a/b) but not reverse-transcriptase inhibitor
(nevirapine) are required for NL4-3-induced BTLA down-regulation. Values represent the percentages of CD41 T cells that express BTLA. D, Pooled data
confirming that NL4-3 isolates down-regulated BTLA expression (percentages and MFI) dependening on IFN-a in vitro. Error bars indicate standard
deviations. *P, .05. E, Representative histograms indicating that NL4-3 exposure induces BTLA down-regulation on CD41 T cells in vitro depending on
plasmacytoid dendritic cell -derived IFN-a. Values represent the percentages and MFI of CD41 T cells that express BTLA.
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[10–13]. In addition, BTLAwas preferentially expressed by naive
CD41 T cells, and its expression significantly decreased with
the T-cell differentiation naive T cells to memory T cells in
HIV-1–infected patients; this pattern is similar to recent data for
patients with melanoma [26] and in a mouse model [17].
Meanwhile, PD-1 and CTLA-4 are seldom expressed by resting
CD41 T cells, and levels are generally elevated in Tem subsets
during HIV-1 infection [12, 14]. These findings open new ave-
nues for studying the role of BTLA in HIV-1 infection.
BTLA also displayed its uniquely functional property differing
from other coinhibitory molecules in HIV-1 infection. It is
generally believed that PD-1 and CTLA-4 up-regulation during
HIV-1 infection can lead to T-cell exhaustion [10–13]. We
proposed that BTLA loss in CD41 T cells may cause generalized
immune activation during HIV-1 infection. The present study
provides several lines of evidence in support of this notion: (1)
BTLA expression on CD4 T cells was negatively associated with
immune activation in HIV-1 infected patients; (2) enhancing
BTLA-mediated inhibitory signaling significantly decreased
TCR- and PMA-induced T-cell activation and cytokine pro-
duction in vitro, but BTLA-mediated inhibitory function is
largely impaired in HIV-1–infected patients, thus promoting
generalized T cell immune activation; and (3) HIV isolate-
induced IFN-a can decrease BTLA expression and increase T-
cell activation. Indeed, other several studies have also demon-
strated that BTLA ligation can send a constitutive ‘‘off ’’ signal to
T cells and maintain T-cell tolerance in vitro [21–23]. BTLA-
deficient mice generally develop an exacerbated autoimmune
disease symptom, suggesting that BTLA silence or down-regu-
lation may increase the abnormal activation of immune cells,
including T cells [24, 25]. Collectively, these findings strongly
suggested that HIV-1 can down-regulate BTLA expression on T
cells, which subsequently causes more nonspecific activation of
T cells to allow for greater replication of HIV-1 in as a positive
feedback loop. Therefore, HIV-1 may manipulate the BTLA
inhibitory pathway for its own survival.
More important, we found that BTLA down-regulation de-
pends on pDC-derived IFN-a induced by HIV-1 isolates;
blockade of IFN-a-mediated pathway or depletion of pDCs
partially blocked NL4-3–induced BTLA down-regulation in vi-
tro. In addition, some anti-HIV reagents targeting HIV-1 entry
(B12) and endocytosis of pDCs (chloroquine) can also effi-
ciently rescue HIV-1–induced BTLA down-regulation. Specially,
chloroquine can specially inhibit pDCs producing type I IFNs
through blocking TLR endocytosis, and it can further decrease
CD8 T-cell activation [35]. These findings, in combination with
Figure 6. B and T lymphocyte attenuator (BTLA)–mediated inhibition on CD41 T-cell activation during human immunodeficiency virus (HIV)–1 infection.
A, Representative histograms depicting the expression of CD38, CD25, and CD69 in CD41 T cells from a healthy subject. Values represent the percentage
of CD41 T cells that express CD38, CD25, and CD69. B, Pooled data showing the fold-inhibition of anti-BTLA cross-linking on anti-CD3-induced CD41 T-
cell activation in HIV-1–infected typical progressors/patients with AIDS (n 5 26) and healthy subjects (n 5 8). C, Representative dot plots show the
effects of anti-BTLA cross-linking on interleukin (IL)-2 and interferon (IFN)–c production of CD41 T cells induced by anti-CD3 or PMA/ionomycin
stimulation in a healthy subject. Values in the 3 quadrants represent the percentages of CD41 T cells that express IFN-c and IL-2. D, Pooled data showing
the fold-inhibition of anti-BTLA cross-linking on IL-2 and IFN-c production of CD41 T cells induced by anti-CD3– and PMA/ionomycin–stimulation in HIV-
infected typical progressors and patients with AIDS (n 5 16) and healthy subjects (n 5 8). In panels B and D, fold-inhibition was calculated as the
differences between the baseline activation marker expression on isotype control antibody stimulation and anti-BTLA antibody stimulation were divided
by the baseline activation marker expression on CD41 T cells with isotype control antibody stimulation. The Mann-Whitney U test was used to compare
data from 2 different groups. P values are shown.
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a recent study demonstrating that CpG can down-regulate
BTLA expression on tumor-specific CD8 T cells in vivo [26],
suggest that pDC-derived IFN-a is likely responsible for the
BTLA down-regulation during HIV-1 infection. These data in-
dicate that multiple virological factors (such as Vpr [36] and Nef
[37]) and immunological factors (such as common c-chain
cytokines [38]) have the ability to regulate the expression of
costimulatory molecules on T cells.
Taken together, this study emphasizes host-autologous
immune regulatory mechanisms, and highlights BTLA down-
regulation may link IFN-a production by pDCs to T-cell over-
activation in HIV-1 infection [6, 39, 40]. Indeed, pDCs-derived
IFN-a has been demonstrated closely with immune activation
in HIV infection [39, 41]. These findings, therefore, shed a new
light on the understanding of coinhibitory molecules in the view
of protective response aiming to restrict damage by an out-of-
control T-cell immune response in HIV-1 infection.
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